Menu Search
Equities

Krystal Biotech Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
4KB:MUN

Krystal Biotech Inc

Actions
  • Price (EUR)226.70
  • Today's Change-3.20 / -1.39%
  • Shares traded5.00
  • 1 Year change+45.65%
  • Beta0.4943
Data delayed at least 15 minutes, as of Feb 06 2026 07:06 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. The Company is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications.

  • Revenue in USD (TTM)373.16m
  • Net income in USD198.91m
  • Incorporated2017
  • Employees275.00
  • Location
    Krystal Biotech Inc2100 Wharton St Ste 701PITTSBURGH 15203-1973United StatesUSA
  • Phone+1 (412) 586-5830
  • Fax+1 (302) 655-5049
  • Websitehttps://www.krystalbio.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.